Alisol B 23-acetate PEG1-C2-Boc [2H]C([2H])(C(=O)N[C@H]1[C@H]2SC(C)(C)[C@H](C([O-])=O)N2C1=O)C1C([2H])=C([2H])C([2H])=C([2H])C=1[2H]

[2H]C([2H])(C(=O)N[C@H]1[C@H]2SC(C)(C)[C@H](C([O-])=O)N2C1=O)C1C([2H])=C([2H])C([2H])=C([2H])C=1[2H]

5-benzodiazepin-3-yl]-2-(methylamino)propanamide

InChi: InChI=1S/C23H17FN6O

It has been studied for the treatment of both Alzheimer's disease and schizophrenia

Alisol B 23-acetate PEG1-C2-Boc [2H]C([2H])(C(=O)N[C@H]1[C@H]2SC(C)(C)[C@H](C([O-])=O)N2C1=O)C1C([2H])=C([2H])C([2H])=C([2H])C=1[2H]Alisol B 23 acetate (23 Acetylalismol B), a natural triterpenoid, produces protective effects against EE induced cholestasis, due to FXR mediated gene regulation. IC50 Value: Target: Anti hepatotoxic natural product. In vitro: Alisol B 23 acetate has an effect on FXR activation in a dose dependent manner using luciferase reporter assay in HepG2 cells . In vivo: In alisol B 23 acetate treated mice, the changes in transporters and enzymes, as well as